• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用高维度基因组数据对甲状腺结节进行分子分类。

Molecular classification of thyroid nodules using high-dimensionality genomic data.

机构信息

Veracyte, Inc., 7000 Shoreline Court Suite 250, South San Francisco, California 94080, USA.

出版信息

J Clin Endocrinol Metab. 2010 Dec;95(12):5296-304. doi: 10.1210/jc.2010-1087. Epub 2010 Sep 8.

DOI:10.1210/jc.2010-1087
PMID:20826580
Abstract

OBJECTIVE

We set out to develop a molecular test that distinguishes benign and malignant thyroid nodules using fine-needle aspirates (FNA).

DESIGN

We used mRNA expression analysis to measure more than 247,186 transcripts in 315 thyroid nodules, comprising multiple subtypes. The data set consisted of 178 retrospective surgical tissues and 137 prospectively collected FNA samples. Two classifiers were trained separately on surgical tissues and FNAs. The performance was evaluated using an independent set of 48 prospective FNA samples, which included 50% with indeterminate cytopathology.

RESULTS

Performance of the tissue-trained classifier was markedly lower in FNAs than in tissue. Exploratory analysis pointed to differences in cellular heterogeneity between tissues and FNAs as the likely cause. The classifier trained on FNA samples resulted in increased performance, estimated using both 30-fold cross-validation and an independent test set. On the test set, negative predictive value and specificity were estimated to be 96 and 84%, respectively, suggesting clinical utility in the management of patients considering surgery. Using in silico and in vitro mixing experiments, we demonstrated that even in the presence of 80% dilution with benign background, the classifier can correctly recognize malignancy in the majority of FNA samples.

CONCLUSIONS

The FNA-trained classifier was able to classify an independent set of FNAs in which substantial RNA degradation had occurred and in the presence of blood. High tolerance to dilution makes the classifier useful in routine clinical settings where sampling error may be a concern. An ongoing multicenter clinical trial will allow us to validate molecular test performance on a larger independent test set of prospectively collected thyroid FNAs.

摘要

目的

我们旨在开发一种使用细针抽吸(FNA)区分良性和恶性甲状腺结节的分子检测方法。

设计

我们使用 mRNA 表达分析测量了 315 个甲状腺结节中的超过 247186 个转录本,包括多个亚型。该数据集由 178 个回顾性手术组织和 137 个前瞻性采集的 FNA 样本组成。两个分类器分别在手术组织和 FNA 上进行训练。使用包含 50%不确定细胞学的 48 个前瞻性 FNA 样本的独立集来评估性能。

结果

组织训练的分类器在 FNA 中的性能明显低于组织。探索性分析表明,组织和 FNA 之间细胞异质性的差异可能是造成这种情况的原因。在 FNA 样本上训练的分类器提高了性能,这是通过 30 倍交叉验证和独立测试集来估计的。在测试集上,阴性预测值和特异性估计分别为 96%和 84%,这表明在考虑手术的患者管理中具有临床应用价值。通过计算机模拟和体外混合实验,我们证明即使在良性背景下存在 80%的稀释,该分类器也可以正确识别大多数 FNA 样本中的恶性肿瘤。

结论

在存在大量 RNA 降解和血液的情况下,FNA 训练的分类器能够对独立的 FNA 样本进行分类。高稀释容忍度使分类器在常规临床环境中很有用,因为采样误差可能是一个问题。正在进行的多中心临床试验将使我们能够在更大的前瞻性收集的甲状腺 FNA 独立测试集中验证分子检测的性能。

相似文献

1
Molecular classification of thyroid nodules using high-dimensionality genomic data.使用高维度基因组数据对甲状腺结节进行分子分类。
J Clin Endocrinol Metab. 2010 Dec;95(12):5296-304. doi: 10.1210/jc.2010-1087. Epub 2010 Sep 8.
2
Molecular Classification of Thyroid Nodules with Indeterminate Cytology: Development and Validation of a Highly Sensitive and Specific New miRNA-Based Classifier Test Using Fine-Needle Aspiration Smear Slides.甲状腺结节的不明细胞学分类:使用细针抽吸涂片建立高敏感和特异的新型 miRNA 分类器检测方法。
Thyroid. 2018 Dec;28(12):1618-1626. doi: 10.1089/thy.2018.0254. Epub 2018 Nov 22.
3
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.术前诊断不确定细胞学的良性甲状腺结节。
N Engl J Med. 2012 Aug 23;367(8):705-15. doi: 10.1056/NEJMoa1203208. Epub 2012 Jun 25.
4
Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules.细胞学不确定甲状腺结节的分子诊断分析性能验证。
J Clin Endocrinol Metab. 2012 Dec;97(12):E2297-306. doi: 10.1210/jc.2012-1923. Epub 2012 Oct 18.
5
Spatial spectral imaging as an adjunct to the Bethesda classification of thyroid fine-needle aspiration specimens.空间频谱成像作为甲状腺细针抽吸标本贝塞斯达分类的辅助手段。
Cancer Cytopathol. 2013 Mar;121(3):162-7. doi: 10.1002/cncy.21224. Epub 2012 Jul 25.
6
Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.基因组测序分类器在术前诊断细胞学不确定的甲状腺结节中的性能。
JAMA Surg. 2018 Sep 1;153(9):817-824. doi: 10.1001/jamasurg.2018.1153.
7
Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.AfiRa 基因组测序分类器与基因表达分类器的性能比较:机构经验。
Cancer Cytopathol. 2019 Nov;127(11):720-724. doi: 10.1002/cncy.22188. Epub 2019 Sep 19.
8
Repeatedly nondiagnostic thyroid fine-needle aspirations do not modify malignancy risk.反复进行的非诊断性甲状腺细针穿刺不会改变恶性风险。
Acta Cytol. 2011;55(6):539-43. doi: 10.1159/000333230. Epub 2011 Dec 9.
9
Repeat thyroid nodule fine-needle aspiration in patients with initial benign cytologic results.对初次细针穿刺细胞学检查结果为良性的患者进行重复甲状腺结节细针穿刺。
Am J Clin Pathol. 2006 May;125(5):698-702. doi: 10.1309/4AXL-DMN1-JRPM-TX5P.
10
A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.四组 miRNA 可准确地区分细针抽吸的恶性和良性甲状腺不定性病变。
Clin Cancer Res. 2012 Apr 1;18(7):2032-8. doi: 10.1158/1078-0432.CCR-11-2487. Epub 2012 Feb 20.

引用本文的文献

1
Development and validation of mRNA expression-based classifiers to predict low-risk thyroid tumors.基于mRNA表达的分类器用于预测低风险甲状腺肿瘤的开发与验证
Front Endocrinol (Lausanne). 2025 Jul 16;16:1600815. doi: 10.3389/fendo.2025.1600815. eCollection 2025.
2
Molecular testing stratifies the risk of structural recurrence in high risk differentiated thyroid cancer: a retrospective cohort study.分子检测对高危分化型甲状腺癌结构复发风险进行分层:一项回顾性队列研究。
Front Endocrinol (Lausanne). 2025 Jan 24;16:1508404. doi: 10.3389/fendo.2025.1508404. eCollection 2025.
3
Uncovering key molecular mechanisms in the early and late-stage of papillary thyroid carcinoma using association rule mining algorithm.
运用关联规则挖掘算法揭示甲状腺乳头癌早晚期的关键分子机制。
PLoS One. 2023 Nov 2;18(11):e0293335. doi: 10.1371/journal.pone.0293335. eCollection 2023.
4
Utility of the Growth Differentiation Factor-15 in the Differential Diagnosis of Follicular-Patterned Lesions of the Thyroid on Cytopathologic and Histopathologic Samples.生长分化因子-15在甲状腺滤泡样病变细胞病理学和组织病理学样本鉴别诊断中的应用
Cureus. 2023 Sep 29;15(9):e46206. doi: 10.7759/cureus.46206. eCollection 2023 Sep.
5
Molecular diagnostics in the evaluation of thyroid nodules: Current use and prospective opportunities.甲状腺结节评估中的分子诊断:当前的应用和未来的机会。
Front Endocrinol (Lausanne). 2023 Feb 24;14:1101410. doi: 10.3389/fendo.2023.1101410. eCollection 2023.
6
Data Integration-Possibilities of Molecular and Clinical Data Fusion on the Example of Thyroid Cancer Diagnostics.数据集成——以甲状腺癌诊断为例的分子与临床数据融合的可能性。
Int J Mol Sci. 2022 Oct 6;23(19):11880. doi: 10.3390/ijms231911880.
7
Thyroid Cancer Screening Using Tumor-Associated DN T Cells as Immunogenomic Markers.使用肿瘤相关DN T细胞作为免疫基因组标记物进行甲状腺癌筛查。
Front Oncol. 2022 May 27;12:891002. doi: 10.3389/fonc.2022.891002. eCollection 2022.
8
Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.甲状腺细胞学不确定结节的分子检测:一项卫生技术评估。
Ont Health Technol Assess Ser. 2022 Apr 1;22(2):1-111. eCollection 2022.
9
Molecular Markers in the Diagnosis of Thyroid Cancer in Indeterminate Thyroid Nodules.不确定甲状腺结节中甲状腺癌诊断的分子标志物
Indian J Surg Oncol. 2022 Mar;13(1):11-16. doi: 10.1007/s13193-020-01112-8. Epub 2020 Jun 6.
10
Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review.基于组学数据的机器学习分析进行患者分层的生物标志物发现研究:范围综述。
BMJ Open. 2021 Dec 6;11(12):e053674. doi: 10.1136/bmjopen-2021-053674.